CY1114155T1 - Πολυμερικες κατασκευες - Google Patents
Πολυμερικες κατασκευεςInfo
- Publication number
- CY1114155T1 CY1114155T1 CY20131100605T CY131100605T CY1114155T1 CY 1114155 T1 CY1114155 T1 CY 1114155T1 CY 20131100605 T CY20131100605 T CY 20131100605T CY 131100605 T CY131100605 T CY 131100605T CY 1114155 T1 CY1114155 T1 CY 1114155T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fusion proteins
- domain
- multilateral
- constructions
- polymerization
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 238000006116 polymerization reaction Methods 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 abstract 1
- 210000003370 receptor cell Anatomy 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
Abstract
Πολυμερικές πρωτεΐνες σύντηξης μιας περιοχής όμοιας με την Ιg της F1t-1 καθίστανται λειτουργικές με την προσθήκη ή σύνδεση μιας ρίζας. Ξενιστές που κωδικοποιούν τις πρωτεΐνες σύντηξης και κύτταρα του υποδοχέα που εκφράζουν τις πρωτεΐνες σύντηξης μπορούν να χρησιμοποιηθούν θεραπευτικά ώστε να εμποδίσουν την νεοαγγείωση σε άτομα με παθολογικές καταστάσεις που σχετίζονται με την νεοαγγείωση. Τέτοιες καταστάσεις περιλαμβάνουν ηλικιακή εκφύλιση της ώχρας κηλίδας, καρκίνο, ψωρίαση, πολλαπλασιαστική διαβητική αμφιβληστροειδοπάθεια, άσθμα, ραγοειδίτιδα, οστεοαρθρίτιδα και ρευματοειδή αρθρίτιδα. Τα ίδια μέσα πολυμερισμού που χρησιμοποιούνται για μια περιοχή όμοια με την Ιg της FΙt-1, δηλαδή ένας συνδετήρας και μια επικράτεια πολυμερισμού, μπορούν να χρησιμοποιηθούν για άλλα πολυπεπτίδια συμπεριλαμβανομένων εξωκυτταρικών υποδοχέων, μεταβλητών περιοχών αντισωμάτων, κυτοκινών, χημοκινών και παραγόντων ανάπτυξης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60888704P | 2004-09-13 | 2004-09-13 | |
US65820905P | 2005-03-04 | 2005-03-04 | |
EP10165159.4A EP2229956B1 (en) | 2004-09-13 | 2005-09-13 | Multimeric constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114155T1 true CY1114155T1 (el) | 2016-08-31 |
Family
ID=36060586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100605T CY1114155T1 (el) | 2004-09-13 | 2013-07-17 | Πολυμερικες κατασκευες |
Country Status (16)
Country | Link |
---|---|
US (4) | US7928072B2 (el) |
EP (2) | EP2229956B1 (el) |
JP (1) | JP4944032B2 (el) |
CN (1) | CN101094688B (el) |
AT (1) | ATE470454T1 (el) |
BR (1) | BRPI0515264B1 (el) |
CY (1) | CY1114155T1 (el) |
DE (1) | DE602005021811D1 (el) |
DK (2) | DK2229956T3 (el) |
ES (2) | ES2347340T3 (el) |
HK (1) | HK1144663A1 (el) |
IL (2) | IL181839A0 (el) |
MX (1) | MX2007002942A (el) |
PL (2) | PL1804835T3 (el) |
PT (2) | PT1804835E (el) |
WO (1) | WO2006031689A2 (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1804835E (pt) * | 2004-09-13 | 2010-10-04 | Genzyme Corp | Construções multiméricas |
EP2203476B1 (en) * | 2007-09-25 | 2016-10-26 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
WO2009105669A2 (en) * | 2008-02-20 | 2009-08-27 | Genzyme Corporation | Angiogenesis inhibition |
WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
US8697654B2 (en) * | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
PT2601214T (pt) | 2010-08-06 | 2017-12-20 | Genzyme Corp | Composições de antagonistas de vegf e utilizações destes |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
DK3357511T3 (da) | 2011-06-30 | 2020-08-03 | Genzyme Corp | Inhibitorer af t-celleaktivering |
DK2744508T3 (en) * | 2011-08-19 | 2018-02-19 | Harvard College | VEGF BINING PROTEIN TO BLOCK ANGIOGENESES |
CN102399292A (zh) * | 2011-09-14 | 2012-04-04 | 盛剑鹏 | 重组干细胞因子与免疫球融合蛋白及其制备 |
US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
WO2013110120A1 (en) | 2012-01-24 | 2013-08-01 | Inter-K Pty Limited | Peptide agents for cancer therapy |
WO2013163419A1 (en) * | 2012-04-25 | 2013-10-31 | Ligacept Llc | Broad spectrum erbb ligand binding molecules and methods for their use |
CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
CN104411718B (zh) * | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
US9637534B2 (en) | 2013-03-13 | 2017-05-02 | Genzyme Corporation | Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
CN106163573A (zh) * | 2014-02-06 | 2016-11-23 | 建新公司 | 用于治疗和预防黄斑变性的组合物及方法 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
CN107207603A (zh) * | 2015-02-03 | 2017-09-26 | 吉安特科技股份有限公司 | 趋化因子‑免疫球蛋白融合多肽,其组合物、制备方法以及用途 |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
CN114805598A (zh) * | 2019-04-28 | 2022-07-29 | 广州市雷德生物科技有限公司 | 促进蛋白二聚体形成的拉链扣结构及其应用 |
AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN116370399A (zh) * | 2021-12-31 | 2023-07-04 | 康码(上海)生物科技有限公司 | 用于病毒的防护和/或治疗的膜剂及其应用 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
ES2092468T3 (es) | 1988-01-22 | 1996-12-01 | Zymogenetics Inc | Metodos para producir analogos de receptores secretados. |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JPH03233530A (ja) | 1990-02-09 | 1991-10-17 | Fuji Photo Optical Co Ltd | カメラ |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US20020032313A1 (en) | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
EP1167384B1 (en) | 1992-10-28 | 2006-12-13 | Genentech, Inc. | HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
FR2702152B1 (fr) | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
JP3734262B2 (ja) | 1993-03-25 | 2006-01-11 | メルク エンド カンパニー インコーポレーテッド | 血管内皮細胞増殖因子阻害剤 |
ATE301201T1 (de) | 1993-06-07 | 2005-08-15 | Vical Inc | Für die gentherapie verwendbare plasmide |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
US6686200B1 (en) | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
JPH10507061A (ja) | 1994-04-28 | 1998-07-14 | ザ ユニバーシティ オブ ミシガン | アデノウイルス中にパッケージされたプラスミドdnaを用いる遺伝子送達ベクターおよびパッケージング細胞株 |
US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948767A (en) | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US5939401A (en) | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US5910487A (en) | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US5747471A (en) | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
DE69628744D1 (de) | 1995-04-17 | 2003-07-24 | Univ Texas System Austin Board | Adenovirus helfervirus system |
US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
AU1695197A (en) | 1996-01-05 | 1997-08-01 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5935936A (en) | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
WO1998013071A1 (en) | 1996-09-24 | 1998-04-02 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Vegf結合性ポリペプチド |
US5925628A (en) | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5912239A (en) | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948925A (en) | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5942634A (en) | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
EP1173191A4 (en) | 1997-05-13 | 2004-12-01 | Univ California | NOVEL ANTI-ANGIOGENIC PEPTIDE AGENTS, USE OF THE SAME FOR THERAPY AND DIAGNOSIS |
US5952916A (en) | 1998-05-28 | 1999-09-14 | Atras Auto Co., Ltd | Hammer-equipped emergency signal device |
DE69832798T2 (de) | 1997-06-03 | 2006-09-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen. |
JP4405597B2 (ja) | 1997-06-18 | 2010-01-27 | メルク エンド カムパニー インコーポレーテッド | ヒト受容体型チロシンキナーゼkdr |
US5963622A (en) | 1997-07-29 | 1999-10-05 | 3Com Corporation | Mode signalling method and apparatus |
CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
EP1183051A2 (en) | 1999-03-15 | 2002-03-06 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
BRPI0011407B8 (pt) * | 1999-06-08 | 2021-05-25 | Regeneron Pharma | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
WO2002024234A2 (en) | 2000-09-20 | 2002-03-28 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
EP1349574A2 (en) | 2001-01-09 | 2003-10-08 | MERCK PATENT GmbH | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
US6886200B2 (en) * | 2001-01-25 | 2005-05-03 | Hill-Rom Services, Inc. | Hydraulic actuator apparatus for a surgical table |
DE10109855A1 (de) * | 2001-03-01 | 2002-09-12 | Stanislawski Thomas | Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
US7078411B2 (en) * | 2001-05-16 | 2006-07-18 | Umdnj (Univ Of Medicine & Dentist. Of Nj) | Phospholipid transfer protein (PLTP) and cholestoral metabolism |
EP1490113A4 (en) | 2002-03-20 | 2007-05-02 | Univ Florida | ADENO-ASSOCIATED RECOMBINANT VIRAL VECTOR (RAAV) COMPOSITIONS AND CORRESPONDING METHODS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION |
CU23178A1 (es) | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
WO2004085479A2 (en) | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Treatment of viral infections |
PT1804835E (pt) * | 2004-09-13 | 2010-10-04 | Genzyme Corp | Construções multiméricas |
MX2007007165A (es) | 2004-12-17 | 2007-08-14 | Genentech Inc | Terapia de antiangiogenesis de enfermedad autoinmune en pacientes en quienes ha fallado la terapia anterior. |
WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
-
2005
- 2005-09-13 PT PT05810409T patent/PT1804835E/pt unknown
- 2005-09-13 DE DE602005021811T patent/DE602005021811D1/de active Active
- 2005-09-13 BR BRPI0515264A patent/BRPI0515264B1/pt not_active IP Right Cessation
- 2005-09-13 DK DK10165159.4T patent/DK2229956T3/da active
- 2005-09-13 WO PCT/US2005/032320 patent/WO2006031689A2/en active Application Filing
- 2005-09-13 CN CN2005800386237A patent/CN101094688B/zh active Active
- 2005-09-13 EP EP10165159.4A patent/EP2229956B1/en active Active
- 2005-09-13 ES ES05810409T patent/ES2347340T3/es active Active
- 2005-09-13 AT AT05810409T patent/ATE470454T1/de active
- 2005-09-13 JP JP2007531408A patent/JP4944032B2/ja active Active
- 2005-09-13 PL PL05810409T patent/PL1804835T3/pl unknown
- 2005-09-13 DK DK05810409.2T patent/DK1804835T3/da active
- 2005-09-13 ES ES10165159T patent/ES2407859T3/es active Active
- 2005-09-13 MX MX2007002942A patent/MX2007002942A/es active IP Right Grant
- 2005-09-13 PT PT101651594T patent/PT2229956E/pt unknown
- 2005-09-13 PL PL10165159T patent/PL2229956T3/pl unknown
- 2005-09-13 EP EP05810409A patent/EP1804835B9/en active Active
-
2007
- 2007-03-11 IL IL181839A patent/IL181839A0/en not_active IP Right Cessation
- 2007-03-12 US US11/716,794 patent/US7928072B2/en active Active
-
2010
- 2010-12-01 HK HK10111185.0A patent/HK1144663A1/xx not_active IP Right Cessation
-
2011
- 2011-02-02 US US13/019,432 patent/US8658602B2/en active Active
- 2011-11-01 IL IL216095A patent/IL216095A/en not_active IP Right Cessation
-
2013
- 2013-07-17 CY CY20131100605T patent/CY1114155T1/el unknown
-
2014
- 2014-01-31 US US14/170,257 patent/US9815892B2/en active Active
-
2017
- 2017-10-17 US US15/785,775 patent/US20180155417A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114155T1 (el) | Πολυμερικες κατασκευες | |
MX2020006408A (es) | Moléculas de unión al antígeno biespecíficas. | |
CY1117241T1 (el) | Αντισωματα anti-igf | |
MX2021004660A (es) | Moleculas de union multivalentes a base de igm- e iga-fc. | |
CY1121558T1 (el) | Διλειτουργικα πολυπεπτιδια | |
CY1124091T1 (el) | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας | |
EP4342912A3 (en) | Binding molecules that modulate a biological activity expressed by a cell | |
CY1119755T1 (el) | Πρωτεϊνες δεσμευομενες με ανθρωπινο αντιγονο c-fms | |
CY1112456T1 (el) | Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6 | |
CY1126121T1 (el) | Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων | |
CY1116037T1 (el) | Αντισωματα κατα της ακτιβινης α και χρησεις αυτων | |
CY1113087T1 (el) | Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4 | |
CY1112840T1 (el) | Πρωτεϊνες συντηξης ταci-ανοσοσφαιρινης | |
IN2015DN01361A (el) | ||
NZ602161A (en) | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof | |
CY1124849T1 (el) | Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων | |
IS7677A (is) | Mótlyf Nogo-viðtaka | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
WO2016179518A8 (en) | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof | |
WO2012040323A3 (en) | Multimeric il-15 soluble fusion molecules and methods of making and using same | |
ATE544854T1 (de) | Mutante g-protein-gekoppelte rezeptoren und selektionsverfahren dafür | |
IS8339A (is) | Mótlyf viðtaka NOGO | |
EA201170030A1 (ru) | Il-6-опосредованная иммунотерапия | |
CY1115960T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα anti-l1 | |
WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer |